A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas

Trial Profile

A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ECHELON-2
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 09 Feb 2017 According to a Seattle Genetics media release, top-line data anticipated in 2018 (previously expected in the 2017 to 2018 timeframe).
    • 08 Nov 2016 According to Seattle Genetics media release, additional four-year follow-up data from this trial will be presented in a poster presentation at the 2016 ASH Annual Meeting.
    • 08 Nov 2016 According to Seattle Genetics media release, results of the ECHELON-2 frontline MTCL study in the 2017 to 2018 timeframe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top